Cidara Therapeutics to Present at the Stifel Healthcare Conference
Cidara Therapeutics (NASDAQ: CDTX) has announced that Jeffrey Stein, Ph.D., President and CEO, will present at the Stifel Healthcare Conference on November 15, 2022, at 4:45 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cidara Therapeutics (NASDAQ: CDTX) has announced that Jeffrey Stein, Ph.D., President and CEO, will present at the Stifel Healthcare Conference on November 15, 2022, at 4:45 PM ET. The presentation will showcase Cidara's developments in long-acting therapeutics aimed at improving patient care. The event will be available for on-demand viewing on the company’s website following the presentation. Cidara focuses on innovative treatments including the Phase 3 antifungal candidate, rezafungin, and drug-Fc conjugates from its proprietary Cloudbreak platform.
Details
News Market Reaction – CDTX
The recorded move for CDTX in the trading session of this news was -1.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference.
| Presentation Information: | |
| Date: | Tuesday, November 15, 2022 |
| Time: | 4:45 PM ET |
| Webcast: | https://wsw.com/webcast/stifel74/cdtx/2101782 |
Cidara’s presentation will be available on-demand from the above date/time in the Investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days.
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.